Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Amylyx Pharmaceuticals, Inc. (AMLX) stock rallied over 5.59% intraday to trade at $20.59 a share on NASDAQ. The stock opened with a loss of -9.01% at $20.14 and touched an intraday high of $22.73, rising 5.59% against the last close of $19.5. The stock went to a low of $18.455 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $20.14 | $22.73 | $18.455 | $20.59 | 1,583,979 |
2022-07-05 | $22.63 | $23.17 | $19.1 | $19.5 | 2,031,100 |
2022-07-01 | $18.85 | $20.35 | $18.74 | $19.47 | 509,800 |
2022-06-30 | $17.83 | $19.67 | $17.82 | $19.26 | 458,700 |
2022-06-29 | $19.39 | $19.783 | $17.68 | $18.18 | 504,100 |
2022-06-28 | $19.55 | $20.14 | $19.06 | $19.68 | 334,200 |
2022-06-27 | $18.83 | $20.44 | $18.42 | $19.93 | 468,800 |
2022-06-24 | $20.03 | $20.3 | $17.85 | $18.71 | 954,000 |
2022-06-23 | $17.68 | $20.74 | $16.97 | $19.8 | 956,700 |
2022-06-22 | $17.09 | $18.61 | $16.295 | $17.55 | 508,400 |
Employees-
Beta-
Sales or Revenue285 Thousands
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stock price is $20.59 as of the last check on Wednesday, July 6. During the trading session, AMLX stock reached the peak price of $22.73 while $18.455 was the lowest point it dropped to.
The NASDAQ listed AMLX is part of Pharmaceuticals industry that operates in the broader Health Care sector. Amylyx Pharmaceuticals, Inc. , a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada.
Ms. Margaret M. Olinger M.B.A
Chief Commercial Officer
Mr. Justin Klee
Co-Founder, Co-CEO & Director
Mr. James M. Frates
Chief Financial Officer
Ms. Margaret M. Olinger M.B.A
Global Head of Commercial & CCO
AMLX stock traded closed the last session at $20.59, which is $1.09 or 5.59% lower than its previous close of $19.5. AMLX's current trading price is 216.28% lower than its 52-week high of $33.41 where as its distance from 52-week low of 6.51% is -38.37%.
Number of AMLX employees currently stands at -. AMLX operates from 43 Thorndike Street, Cambridge, MA 02141, United States.
Official Webiste of $AMLX is: https://amylyx.com
AMLX could be contacted at AMLX operates from 43 Thorndike Street, Cambridge, MA 02141, United States, or at phone #617 682 0917 and can also be accessed through its website.
AMLX stock volume for the day was 1,667,735 shares while in the previous session number of AMLX shares traded was 1,583,979 . The average number of AMLX shares traded daily for last 3 months was 776.2 Thousands.
The percentage change in AMLX stock occurred in the recent session was 5.59% while the dollar amount for the price change in AMLX stock was $1.09.
In the recent session, the day high for AMLX stock was $22.73 while the low for AMLX stock touched on the day was $18.455.
The market value of AMLX currently stands at 1.19 Billion with its latest stock price at $20.59 and 51.6 Million of its shares outstanding.